TACE联合RFA治疗复发性肝癌的生存期分析  

Survival Analysis of Patients with Recurrent Hepatocellular Carcinoma Treated by TACE Combined with RFA

作　　者：白涛[1,2,3] 叶甲舟 陈洁[1,2,3] 黎乐群 吴飞翔[1,2,3] BAI Tao;YE Jia-zhou;CHEN Jie;LI Le-qun;WU Fei-xiang(Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China;Guangxi Engineering and Technology Center for Diagnosis and Treatment Research of Liver Cancer,Nanning 530021,China;Key Laboratory of High-Incidence-Tumor Early Prevention and Treatment,Ministry of Education,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院,广西南宁530021 [2]广西肝癌诊疗工程技术研究中心,广西南宁530021 [3]区域性高发肿瘤早期防治研究教育部重点实验室,广西南宁530021

出　　处：《肿瘤学杂志》2018年第8期779-782,共4页Journal of Chinese Oncology

基　　金：区域性高发肿瘤早期防治研究教育部重点实验室(GKZ201604);广西卫计委重点课题(S201513);广西科学技术厅重点研发课题(桂科AB16380242);广西高校中青年教师基础能力提升项目(2017KY0115);北京医卫健康公益基金会《医学科学研究基金资助项目》(YWJKJHKYJJ-A310)

摘　　要：[目的]研究经肝动脉插管化疗栓塞术（TACE）联合射频消融术（RFA）治疗复发性肝癌总生存期及其影响因素。[方法]选取复发性肝癌患者106例,分为对照组和观察组,每组53例。对照组患者行RFA治疗,观察组患者接受TACE联合RFA治疗,术后均随访3年。比较两组患者的术后无瘤生存率、总生存率和并发症发生率,单因素和多因素分析总生存期的影响因素。[结果]观察组术后1年和2年无瘤生存率均明显高于对照组（P〈0.01）,术后2年和3年总生存率均明显高于对照组（P〈0.01）。多因素分析显示,复发时间是总生存期的独立影响因素（P〈0.01）。两组患者的并发症发生率差异统计学意义（P〉0.05）。[结论]TACE联合RFA治疗复发性肝癌可明显延长患者的生存期,复发时间是影响总生存期的主要因素。[Objective] To analyze the survival and influencing factors of patients with recurrent hepatocellular carcinoma treated by transcatheter arterial chemoembolization（TACE） combined with radiofrequency ablation（RFA）. [Methods] One hundred and six patients with recurrent hepatocellular carcinoma were divided into two groups with 53 cases in each group. Patients in the control group received RFA treatment and patients in study group received TACE combined with RFA. All patients were followed up for 3 years. The disease-free survival rate,overall survival rate,and complication rate after treatments were compared between the two groups. The factors influencing the overall survival were analyzed by univariate and multivariate analysis. [Results] The1-and 2-year disease-free survival rates in the study group were significantly higher than those in the control group（P〈0.01）. The overall 2-and 3-year survival rates in the study group were significantly higher than those in control group（P〈0.01）. Multivariate analysis showed that recurrence time was an independent factor of overall survival（P〈0.01）. There was no significant difference in the incidence of postoperative complications between the two groups（P〉0.05）.[Conclusion] TACE combined with RFA can significantly prolong the survival of patients with recurrent hepatocellular carcinoma. Recurrence time is the main factor affecting the overall survival.

关 键 词：TACE RFA 复发性肝癌 生存期 

分 类 号：R735.7[医药卫生—肿瘤]